Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: A phase II study.

被引：0
|
作者：
Bartlett, Nancy
Brice, Pauline
Chen, Robert W.
Fanale, Michelle A.
Gopal, Ajay K.
Matous, Jeffrey
Rosenblatt, Joseph David
Grove, Laurie E.
Forero-Torres, Andres
机构：
[1] Washington Univ, Siteman Canc Ctr, St Louis, MO USA
[2] Hosp Saint Louis, Paris, France
[3] City Hope Natl Med Ctr, Duarte, CA USA
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
[6] Colorado Blood Canc Inst, Denver, CO USA
[7] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA
[8] Seattle Genet Inc, Bothell, WA USA
[9] Univ Alabama Birmingham, Birmingham, AL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8027
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
    Nancy L Bartlett
    Robert Chen
    Michelle A Fanale
    Pauline Brice
    Ajay Gopal
    Scott E Smith
    Ranjana Advani
    Jeffrey V Matous
    Radhakrishnan Ramchandren
    Joseph D Rosenblatt
    Dirk Huebner
    Pamela Levine
    Laurie Grove
    Andres Forero-Torres
    Journal of Hematology & Oncology, 7
  • [2] Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
    Bartlett, Nancy L.
    Chen, Robert
    Fanale, Michelle A.
    Brice, Pauline
    Gopal, Ajay
    Smith, Scott E.
    Advani, Ranjana
    Matous, Jeffrey V.
    Ramchandren, Radhakrishnan
    Rosenblatt, Joseph D.
    Huebner, Dirk
    Levine, Pamela
    Grove, Laurie
    Forero-Torres, Andres
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2014, 7
  • [3] RETREATMENT WITH BRENTUXIMAB VEDOTIN IN CD30 POSITIVE HEMATOLOGIC MALIGNANCIES: A PHASE 2 STUDY
    Forero-Torres, A.
    Brice, P.
    Chen, R.
    Fanale, M.
    Gopal, A.
    Matous, J.
    Rosenblatt, J.
    Grove, L.
    Bartlett, N.
    HAEMATOLOGICA, 2012, 97 : 85 - 86
  • [4] Objective responses with brentuximab vedotin (SGN-35) retreatment in CD30-positive hematologic malignancies: A case series
    Bartlett, N.
    Grove, L. E.
    Kennedy, D. A.
    Sievers, E. L.
    Forero-Torres, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
    Fanale, Michelle A.
    Forero-Torres, Andres
    Rosenblatt, Joseph D.
    Advani, Ranjana H.
    Franklin, Anna R.
    Kennedy, Dana A.
    Han, Tae H.
    Sievers, Eric L.
    Bartlett, Nancy L.
    CLINICAL CANCER RESEARCH, 2012, 18 (01) : 248 - 255
  • [6] Brentuximab vedotin for CD30-positive tumours
    Masuda, Shigeo
    Miyagawa, Shigeru
    Nakamura, Terumi
    Khurram, Maaz Asher
    Sawa, Yoshiki
    LANCET ONCOLOGY, 2016, 17 (09): : E371 - E371
  • [7] PERIPHERAL NEUROTOXICITY IN PATIENTS WITH CD30-POSITIVE MALIGNANCIES, TREATED WITH BRENTUXIMAB VEDOTIN
    Plasmati, R.
    Pastorelli, F.
    Salvi, F.
    Zinzani, P. L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2013, 18 : 26 - 27
  • [8] PERIPHERAL NEUROTOXICITY IN PATIENTS WITH CD30-POSITIVE MALIGNANCIES, TREATED WITH BRENTUXIMAB VEDOTIN
    Plasmati, R.
    Pastorelli, F.
    Salvi, F.
    Zinzani, P. L.
    JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2012, 17 : S46 - S46
  • [9] Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies
    Han, T. H.
    Chen, R.
    Advani, R.
    Berryman, R. B.
    Smith, S. E.
    Forero-Torres, A.
    Rosenblatt, J. D.
    Smith, M. R.
    Zain, J.
    Hunder, N. N.
    Engert, A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 241 - 249
  • [10] Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies
    T. H. Han
    R. Chen
    R. Advani
    R. B. Berryman
    S. E. Smith
    A. Forero-Torres
    J. D. Rosenblatt
    M. R. Smith
    J. Zain
    N. N. Hunder
    A. Engert
    Cancer Chemotherapy and Pharmacology, 2013, 72 : 241 - 249
12345